Equities Analysts Offer Predictions for ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at B. Riley increased their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Thursday, February 13th. B. Riley analyst M. Mamtani now anticipates that the biotechnology company will post earnings per share of $1.15 for the year, up from their prior estimate of $1.00. B. Riley currently has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.40) per share.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97).

A number of other brokerages have also recently commented on ARWR. Sanford C. Bernstein cut their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Piper Sandler cut their target price on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Citigroup cut their price objective on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Finally, StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $41.44.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $19.95 on Monday. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The company has a 50-day moving average of $20.00 and a 200-day moving average of $21.05. Arrowhead Pharmaceuticals has a 52 week low of $17.05 and a 52 week high of $36.72. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of -3.97 and a beta of 0.95.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently modified their holdings of ARWR. International Assets Investment Management LLC bought a new position in Arrowhead Pharmaceuticals in the third quarter valued at approximately $14,420,000. Assenagon Asset Management S.A. boosted its position in shares of Arrowhead Pharmaceuticals by 232.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 293,083 shares of the biotechnology company’s stock worth $5,677,000 after purchasing an additional 204,933 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth $52,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Arrowhead Pharmaceuticals by 79.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 14,498 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 6,424 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 32,729 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $648,688.78. Following the transaction, the insider now directly owns 272,122 shares in the company, valued at approximately $5,393,458.04. This trade represents a 10.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 26,712 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $21.24, for a total value of $567,362.88. Following the sale, the chief executive officer now owns 3,688,335 shares of the company’s stock, valued at approximately $78,340,235.40. The trade was a 0.72 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 147,432 shares of company stock worth $2,957,986. 4.30% of the stock is currently owned by corporate insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.